Compare Coursera Inc (COUR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Coursera Inc trades at $5.24 (market cap $1.39B), while State Street SPDR S&P Biotech ETF trades at $154.11 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 7.3× Coursera Inc's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coursera Inc for 47 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| COUR | XBI | |
|---|---|---|
Market Cap | $1.39B | $10.11B |
Volume | 9,728,980 | 12,903,266 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $10.73 | $169.55 |
52-Week Low | $4.64 | $104.99 |
Typical Hold Time | 47 Days | 37 Days |
Enterprise Value | $648.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.11, down 0.2% with bearish technical signals despite positive analyst sentiment. The company shows improving revenue growth from $524M in 2022 to $758M in 2025, though net losses persist at -$51M. Recent news highlights strong institutional interest with Deutsche Bank acquiring 1.7M shares and unusual options activity indicating bullish speculation. The stock faces technical resistance at $5 with RSI suggesting potential overbought conditions near-term.
While analyst consensus remains bullish with a $7.40 price target (44% upside), execution risks from ongoing losses and competitive pressures in edtech warrant caution. The company's Project Helix AI platform and 44% subscriber growth provide catalysts, but profitability challenges and integration costs from recent acquisitions present headwinds for investor returns.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
